Histone deacetylases in RA: epigenetics and epiphenomena
Grabiec, A.M.; Reedquist, K.A.

Published in:
Arthritis Research & Therapy

DOI:
10.1186/ar3137

Citation for published version (APA):
In the previous issue of Arthritis Research & Therapy, Kawabata and colleagues [1] examined the activity and expression of histone deacetylases (HDACs) in the synovial tissue of patients with rheumatoid arthritis (RA) in relation to local tumor necrosis factor-alpha (TNFα) production. The authors found that total HDAC activity was increased in RA synovial tissue compared with osteoarthritis (OA) disease control and normal control tissues. Expression of HDAC1 was significantly elevated in RA among HDACs examined. Similarly, HDAC1 expression was elevated in RA fibroblast-like synoviocytes (FLSs) compared with OA FLSs. Both total synovial HDAC activity and HDAC1 expression were associated with increased TNFα production, and in attempting to understand the cellular basis of this relationship, the authors found that TNFα stimulation of RA FLSs led to transient increases in cellular HDAC activity and HDAC1 expression. This report is noteworthy for the efforts of the authors to resolve apparent discrepancies between their data and the published literature [2] and for the resulting new questions regarding how HDACs might contribute to RA.

Histone acetyltransferases (HATs) and HDACs reciprocally regulate the acetylation status of cellular proteins. Acetylation of histones promotes unwinding of compacted chromatin and allows access of transcription factors to gene promoter regions, and by extension, changes in relative HAT/HDAC activity would be expected to influence the sensitivity of cellular gene transcription in response to extracellular stimuli. This epigenetic mechanism of gene regulation has been suggested to contribute to pathology in complex immune-mediated inflammatory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, in which depressed HDAC activity at the site of inflammation, especially in macrophages, is associated with disease severity and inflammatory cytokine production and contributes to glucocorticoid resistance [3]. An initial examination of HAT and HDAC activity in RA synovial tissue [2] painted a picture suggesting many similarities with COPD and asthma [4], noting depressed synovial HDAC activity in RA tissue compared with OA and normal donor tissues, particularly in regard to HDAC1 and HDAC2 expression. This initial study suggests that decreased HDAC activity may contribute to pathology in RA (and render RA patients resistant to future treatment with HDAC inhibitors) [2]. Kawabata and colleagues, in contrast, argue that increased HDAC1 activity may contribute to RA and represent a new therapeutic target [1].

The studies conducted by both groups are technically impeccable, ruling out many trivial explanations for discordant results. However, Kawabata and colleagues noted that none of the patients they examined was treated with TNFα-blocking biologicals and that synovial TNFα production significantly correlated with HDAC activity and HDAC1 expression. In contrast, a substantial
number of the RA patients studied by Huber and colleagues [2] received TNFα-blocking therapies, raising the possibility that TNFα drives HDAC expression and activity. Although independent analyses of larger patient cohorts and prospective clinical studies are needed to substantiate this idea in vivo, initial in vitro experiments showing that TNFα stimulation induces RA FLS HDAC activity and HDAC1 expression [1] are compelling.

Several aspects of these two studies deserve further exploration. Variation in HDAC activity and expression between RA and non-inflammatory OA observed by both groups is modest, and little is known about the magnitude of fluctuation in cellular HDAC activity sufficient to modify inflammatory responses. Analyses of mice expressing only single alleles of specific HDACs in experimental arthritis models may be useful in answering this question. It is also uncertain whether altered synovial HDAC activity influences therapeutic strategies targeting the balance of synovial protein acetylation, as HDAC inhibitors are uniformly effective in animal models of RA [5] and demonstrate anti-inflammatory properties in RA FLSs [6], synovial macrophages, and synovial biopsy explants [7]. Kawabata and colleagues also provide evidence strengthening the hypothesis that HDACs are intimately involved in inflammatory signal transduction pathways in RA. The timing of changes in HDAC activity and expression following TNFα stimulation corresponds with the involvement of signaling proteins required for FLS cytokine responses, including nuclear factor-kappa-B (NF-κB) p65, JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling components, AP-1 (activator protein-1), and p53. These proteins are regulated by reversible acetylation [5], and the biochemical effects of acetylation (regulation of protein activation, localization, stability, and target specificity) are as diverse as those regulated by phosphorylation [8]. Indeed, recent evidence has demonstrated that, in transformed RA FLSs, HDAC inhibitors prevent activation of NF-κB p65 [9].

Finally, while HDAC1 is the most prominent Class I/II HDAC in RA synovial and FLS [1,6], silencing of either HDAC1 or HDAC2 have similar effects on FLS survival and proliferation [6]. This may suggest either that there are numerous redundancies in HDAC target specificity, or that bulk HDAC activity is most relevant to inflammatory and pro-survival gene expression in RA, important in considering whether inhibition of specific HDACs will be needed in therapeutic strategies. Reaching a consensus on the expression and activity of new biological targets in RA is a critical step in the evaluation of their role and therapeutic potential. However, as exemplified by the burst of recent research on HDAC biology in RA, the initial disparate results and conclusions are what accelerate our drive to spark the most intriguing questions and reach this consensus.

References


Abbreviations

COPD, chronic obstructive pulmonary disease; FLS, fibroblast-like synoviocyte; HAT, histone acetyltransferase; HDAC, histone deacetylase; NF-κB, nuclear factor kappa-B; OA, osteoarthritis; RA, rheumatoid arthritis; TNFα, tumor necrosis factor-alpha.

Competing interests

The authors declare that they have no competing interests.

Published: 11 October 2010